ABSTRACT
Background Detection of circulating tumour DNA (ctDNA) after curative intent treatment reflects the presence of minimal residual disease and predicts for recurrence. DYNAMIC trial is a randomised phase II investigating the clinical utility of ctDNA-guided adjuvant treatment strategy compared with the standard of care (non-ctDNA based) approach in patients with stage II colon cancer. The primary trial endpoint is recurrence-free survival estimated from Kaplan Meier Method at 2 years. Secondary endpoints include proportion of patients treated with adjuvant chemotherapy, time-to-recurrence, overall survival, ctDNA clearance rate (investigational arm) and quality-adjusted life-years.
Objective To outline and publish the pre-determined statistical analysis plan (SAP) before the database lock and the start of analysis.
Methods The SAP describes basic analysis principles, methods for dealing with a range of commonly encountered data analysis issues and the specific statistical procedures for analysing efficacy and safety outcomes. The SAP was approved after closure of recruitment and before completion of patient follow-up. It outlines the planned primary analyses and a range of subgroup and sensitivity analyses regarding the clinical outcomes. Health economic outcomes are not included in this plan but will be analysed separately. The SAP will be adhered to for the final data analysis of this trial to avoid analysis bias arising from knowledge of the data.
Trial Registration ANZ Clinical Trials Registry, ACTRN12615000381583. Registered on 27th April 2015.
Competing Interest Statement
BV is founder of, and hold equity in Thrive Earlier Detection and Personal Genome Diagnostics. KWK & NP are on the Board of Directors of, and consultants to, Thrive Earlier Detection. BV is consultant to and hold equity in NeoPhore. BV is a consultant to and holds equity in Catalio Capital Management. All other authors declare no competing interests.
Clinical Trial
ACTRN12615000381583
Funding Statement
This research is funded by: Australian National Health and Medical Research Council (NHMRC APP1085531); Medical Research Future Fund/NHMRC Investigators Grant (APP1194970)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Melbourne Health Human and Research Ethics Committee provided approval of the study protocol and patient consent form
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data availability is not applicable for this manuscript
